直播 | Clinical Pharmacology of Cell-based Cancer Immunotherapies

About the Topic

为期半天的研讨会将讨论基于细胞疗法在肿瘤免疫的临床药理最新进展。演讲报告将专注临床药理学的新趋势和新方法，同时探讨我们面临的一些新的挑战。

Sue received her PhD focused on mechanism based PK/PD modeling from University at Buffalo in 2016. She then joined Novartis PK Sciences Oncology group where she is the clinical pharmacology lead spanning different modalities from research to early and late clinical development.  Sue is currently at the AstraZeneca Quantitative Clinical Pharmacology Group in oncology as the clin pharm lead on cell therapy and bispecific programs, and also serves as the clin pharm subject matter expert in cell therapy.

Yaming Su is currently working for Janssen Pharmaceutical R&D as Scientific Director at Clinical Pharmacology and Pharmacometrics Department.

He supports drug development of both small molecules and biologics primarily in oncology therapeutic areas. He has 16+ years of pharmaceutical industry work experience and has direct involvement in leading the clinical pharmacology and/or pharmacometrics efforts for the successful approval of >10 BLA/sBLA and NDA in oncology and immunology.

Yaming completed his BSc, MSc and PhD in pharmaceutical sciences, biology and pharmaceutics, respectively.

Louis Joslyn is a Senior Scientist in Preclinical & Translational Pharmacokinetics/Pharamcodynamics at Genentech. His work primarily focuses on the development of quantitative systems pharmacology models for T cell therapies, engineered cytokines, and bispecific molecules. He has previous experience developing virtual patient models to characterize the T cell response during TB infection and/or vaccination.  Louis graduated with a PhD in Bioinformatics from the University of Michigan Medical School. Broadly, Louis is motivated to impact drug development by using multimodal approaches to untangle the complexity of the immune system, particularly under the context of disease. 

Weize Huang is currently a Principal Scientist in Genentech Clinical Pharmacology, he has been clinical pharmacology lead and modeling & simulation lead on multiple programs with different therapeutic modalities such as small molecule, mAb, bispecifics, and T cell therapy, over both solid tumor and hematological malignancy disease areas. He is mainly responsible for supporting model-informed clinical drug development (MIDD), implementing dose optimization strategy, performing POPPK, ER, PBPK, and QSP modeling and analysis, and determining RP2D/pivotal dose. Before Genentech, Weize obtained his Pharm.D. & Ph.D. degrees in Pharmaceutics from the University of Washington, Seattle, where he established mechanistic PBPK models to enable in vitro-to-in vivo extrapolation (IVIVE) and describe systemic and renal dispositions of drugs and metabolites in various clinical scenarios including co-medication/drug-drug interaction, organ impairment, pediatrics, and so on.

Jing Nie, is currently the Head of Clinical Pharmacology, Pharmacometrics and bioanalysis at Abbisko. Jing has 13+ years of pharmaceutical industry work experience. After working as a modeling and simulation scientist at Roche US she went back to China. Prior to joining Abbisko, she served as Head of Clinical Pharmacology at ZaiLab, Hematology Oncology TA head at Janssen china clinical pharmacology and pharmacometrics group and clin pharm lead at Novartis Oncology Clinpharm group, where she was responsible or overseeing for the overall clinical pharmacology and quantitative pharmacology strategy for products, including small molecules, large molecules (monoclonal and bispecific drugs) and cellular therapies.

Jing obtained her PhD at the joint lab of Prof. R. Almon and Prof. William Jusko from SUNY buffalo. She has been an advocate for the application of quantitative platforms for data-driven decision making in the early clinical development community in China. She is currently the co-leader of the DIA Clinical Pharmacology Community Core Working Group and Quantitative Pharmacology Committee member of the Chinese Society of Pharmacology.

关于DIA中国临床药理社区（CPC）

定位：临床药理学是一门既关注“药物”，又关心“疾病”的交叉学科。

使命：推动临床药理学科发展，培养系统的临床药理学研究人员，促进医药结合、基础与临床结合、提升新药转化与临床研究的效率和可预见性，指导临床合理用药，推动创新药可持续化发展。

愿景：加速我国临床药理学发展，推动跨学科合作互赢，群策群力助力创新药研发的科学理性与可持续性发展。

点解了解详情，预约直播

微信号｜DIA发布